Company Intelligence
Innovent Biologics
信达生物
HK: 1801Suzhou, Jiangsu, ChinaFounded 2011
BIOSECURE
No Known BCC Exposure
Innovent is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. No 1260H listing. Licensing deals with Innovent do not create federal contracting risk.
2
Tracked Deals
3
Therapeutic Areas
4
Modalities
Overview
Innovent Biologics (信达生物) is one of China's leading biopharmaceutical companies, with a strong oncology and autoimmune pipeline. Known for its PD-1 inhibitor sintilimab (one of China's top-selling cancer drugs) and its expanding bispecific antibody portfolio. Innovent has partnerships with Eli Lilly and is advancing multiple assets with ex-China licensing potential.
Key Facts
- Sintilimab is one of China's best-selling PD-1 inhibitors with $800M+ annual revenue
- Advancing next-generation PD-1/VEGF bispecific into Phase III — a direct competitor to Akeso's ivonescimab
- Strategic collaboration with Eli Lilly for oncology portfolio
- Pipeline includes 30+ clinical-stage candidates
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Takeda | Oct 2025 | $1.2B upfront / $10B+ total | IBI363 + IBI343 (bispecific + ADC, solid tumors) |
| Eli Lilly | 2015-ongoing | $1.4B+ | Oncology portfolio collaboration |
Corporate Structure
Cayman Islands holding company, Hong Kong-listed. Operating subsidiary: Innovent Biologics (Suzhou) Co., Ltd. No VIE structure. Major investors include Eli Lilly (minority stake).